Drug Manufacturers - Specialty & Generic
Compare Stocks
5 / 10Stock Comparison
RMTI vs BDX vs BAX vs ICU vs HOLX
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
Medical - Instruments & Supplies
Biotechnology
Medical - Instruments & Supplies
RMTI vs BDX vs BAX vs ICU vs HOLX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Medical - Instruments & Supplies | Medical - Instruments & Supplies | Biotechnology | Medical - Instruments & Supplies |
| Market Cap | $33M | $54.14B | $9.29B | $27M | $16.97B |
| Revenue (TTM) | $17.39B | $21.36B | $11.32B | $881K | $4.13B |
| Net Income (TTM) | $-1.61B | $1.14B | $-1.10B | $-14M | $544M |
| Gross Margin | 16.7% | 46.5% | 30.1% | 95.3% | 52.8% |
| Operating Margin | -8.5% | 10.6% | -2.7% | -15.8% | 17.5% |
| Forward P/E | — | 11.9x | 9.4x | — | 17.2x |
| Total Debt | $12M | $19.18B | $10.00B | $574K | $2.63B |
| Cash & Equiv. | $16M | $851M | $1.97B | $2M | $1.96B |
RMTI vs BDX vs BAX vs ICU vs HOLX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 22 | May 26 | Return |
|---|---|---|---|
| Rockwell Medical, I… (RMTI) | 100 | 63.2 | -36.8% |
| Becton, Dickinson a… (BDX) | 100 | 108.5 | +8.5% |
| Baxter Internationa… (BAX) | 100 | 33.4 | -66.6% |
| SeaStar Medical Hol… (ICU) | 100 | 1.7 | -98.3% |
| Hologic, Inc. (HOLX) | 100 | 117.2 | +17.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RMTI vs BDX vs BAX vs ICU vs HOLX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Among these 5 stocks, RMTI doesn't own a clear edge in any measured category.
BDX ranks third and is worth considering specifically for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 0.62, yield 2.8%
- Rev growth 8.2%, EPS growth -0.5%, 3Y rev CAGR 5.0%
- 2.8% yield, 1-year raise streak, vs BAX's 3.8%, (3 stocks pay no dividend)
BAX is the clearest fit if your priority is value.
- Better valuation composite
ICU is the #2 pick in this set and the best alternative if growth and momentum is your priority.
- 12.0% revenue growth vs RMTI's -31.8%
- +262.1% vs BAX's -41.2%
HOLX carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.
- 124.3% 10Y total return vs BDX's 76.4%
- Lower volatility, beta 0.45, Low D/E 52.0%, current ratio 3.75x
- Beta 0.45, current ratio 3.75x
- 13.2% margin vs ICU's -15.5%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 12.0% revenue growth vs RMTI's -31.8% | |
| Value | Better valuation composite | |
| Quality / Margins | 13.2% margin vs ICU's -15.5% | |
| Stability / Safety | Beta 0.45 vs BAX's 1.38, lower leverage | |
| Dividends | 2.8% yield, 1-year raise streak, vs BAX's 3.8%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +262.1% vs BAX's -41.2% | |
| Efficiency (ROA) | 6.1% ROA vs RMTI's -28.6%, ROIC 9.4% vs -11.0% |
RMTI vs BDX vs BAX vs ICU vs HOLX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
RMTI vs BDX vs BAX vs ICU vs HOLX — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
HOLX leads in 3 of 6 categories
RMTI leads 0 • BDX leads 0 • BAX leads 0 • ICU leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
HOLX leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
BDX is the larger business by revenue, generating $21.4B annually — 24250.9x ICU's $881,000. HOLX is the more profitable business, keeping 13.2% of every revenue dollar as net income compared to ICU's -15.5%. On growth, RMTI holds the edge at +915.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $17.4B | $21.4B | $11.3B | $881,000 | $4.1B |
| EBITDAEarnings before interest/tax | -$1.5B | $4.2B | $671M | -$14M | $974M |
| Net IncomeAfter-tax profit | -$1.6B | $1.1B | -$1.1B | -$14M | $544M |
| Free Cash FlowCash after capex | $2M | $3.1B | $501M | -$14M | $1000M |
| Gross MarginGross profit ÷ Revenue | +16.7% | +46.5% | +30.1% | +95.3% | +52.8% |
| Operating MarginEBIT ÷ Revenue | -8.5% | +10.6% | -2.7% | -15.8% | +17.5% |
| Net MarginNet income ÷ Revenue | -9.3% | +5.3% | -9.7% | -15.5% | +13.2% |
| FCF MarginFCF ÷ Revenue | +0.0% | +14.7% | +4.4% | -16.1% | +24.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +915.6% | -10.6% | +2.9% | +169.1% | +2.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +9.9% | -2.0% | -112.0% | +88.2% | -9.2% |
Valuation Metrics
Evenly matched — RMTI and BAX each lead in 2 of 6 comparable metrics.
Valuation Metrics
At 25.6x trailing earnings, BDX trades at a 16% valuation discount to HOLX's 30.5x P/E. On an enterprise value basis, BDX's 14.4x EV/EBITDA is more attractive than BAX's 25.7x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $33M | $54.1B | $9.3B | $27M | $17.0B |
| Enterprise ValueMkt cap + debt − cash | $30M | $72.5B | $17.3B | $26M | $17.6B |
| Trailing P/EPrice ÷ TTM EPS | -5.56x | 25.63x | -10.28x | -0.68x | 30.53x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 11.90x | 9.37x | — | 17.21x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.55x | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 14.38x | 25.74x | — | 17.39x |
| Price / SalesMarket cap ÷ Revenue | 0.47x | 2.48x | 0.83x | 198.80x | 4.14x |
| Price / BookPrice ÷ Book value/share | 0.81x | 1.69x | 1.51x | — | 3.43x |
| Price / FCFMarket cap ÷ FCF | — | 20.28x | 28.75x | — | 18.44x |
Profitability & Efficiency
HOLX leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
HOLX delivers a 11.0% return on equity — every $100 of shareholder capital generates $11 in annual profit, vs $-46 for RMTI. RMTI carries lower financial leverage with a 0.34x debt-to-equity ratio, signaling a more conservative balance sheet compared to BAX's 1.64x. On the Piotroski fundamental quality scale (0–9), BDX scores 7/9 vs RMTI's 3/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -45.9% | +4.5% | -16.5% | -119.2% | +11.0% |
| ROA (TTM)Return on assets | -28.6% | +2.1% | -5.4% | -88.0% | +6.1% |
| ROICReturn on invested capital | -11.0% | +4.3% | -1.4% | — | +9.4% |
| ROCEReturn on capital employed | -10.1% | +5.4% | -1.7% | — | +8.8% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 7 | 5 | 6 | 7 |
| Debt / EquityFinancial leverage | 0.34x | 0.76x | 1.64x | — | 0.52x |
| Net DebtTotal debt minus cash | -$3M | $18.3B | $8.0B | -$1M | $667M |
| Cash & Equiv.Liquid assets | $16M | $851M | $2.0B | $2M | $2.0B |
| Total DebtShort + long-term debt | $12M | $19.2B | $10.0B | $574,000 | $2.6B |
| Interest CoverageEBIT ÷ Interest expense | -5.27x | 4.09x | -0.83x | -209.88x | 8.00x |
Total Returns (Dividends Reinvested)
Evenly matched — BDX and ICU and HOLX each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HOLX five years ago would be worth $11,678 today (with dividends reinvested), compared to $175 for ICU. Over the past 12 months, ICU leads with a +262.1% total return vs BAX's -41.2%. The 3-year compound annual growth rate (CAGR) favors BDX at 0.8% vs ICU's -54.9% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -3.0% | -1.8% | -7.7% | +70.7% | +1.9% |
| 1-Year ReturnPast 12 months | -28.7% | +47.3% | -41.2% | +262.1% | +35.3% |
| 3-Year ReturnCumulative with dividends | -70.9% | +2.6% | -55.2% | -90.8% | -8.5% |
| 5-Year ReturnCumulative with dividends | -91.8% | +10.9% | -73.7% | -98.3% | +16.8% |
| 10-Year ReturnCumulative with dividends | -98.9% | +76.4% | -41.3% | -98.3% | +124.3% |
| CAGR (3Y)Annualised 3-year return | -33.8% | +0.8% | -23.5% | -54.9% | -2.9% |
Risk & Volatility
HOLX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
HOLX is the less volatile stock with a 0.45 beta — it tends to amplify market swings less than BAX's 1.38 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HOLX currently trades 100.0% from its 52-week high vs RMTI's 39.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.00x | 0.62x | 1.38x | 1.14x | 0.45x |
| 52-Week HighHighest price in past year | $2.10 | $205.52 | $32.68 | $5.08 | $76.04 |
| 52-Week LowLowest price in past year | $0.74 | $100.31 | $15.73 | $0.22 | $53.62 |
| % of 52W HighCurrent price vs 52-week peak | +39.7% | +72.7% | +55.0% | +88.3% | +100.0% |
| RSI (14)Momentum oscillator 0–100 | 32.6 | 50.9 | 49.4 | 65.5 | 69.1 |
| Avg Volume (50D)Average daily shares traded | 261K | 2.5M | 8.7M | 151K | 10.3M |
Analyst Outlook
Evenly matched — BDX and BAX each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: BDX as "Hold", BAX as "Hold", HOLX as "Hold". Consensus price targets imply 15.7% upside for BDX (target: $173) vs 3.9% for HOLX (target: $79). For income investors, BAX offers the higher dividend yield at 3.77% vs BDX's 2.79%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | Hold | — | Hold |
| Price TargetConsensus 12-month target | — | $172.85 | $20.00 | — | $79.00 |
| # AnalystsCovering analysts | — | 34 | 36 | — | 42 |
| Dividend YieldAnnual dividend ÷ price | — | +2.8% | +3.8% | — | — |
| Dividend StreakConsecutive years of raises | — | 1 | 0 | — | — |
| Dividend / ShareAnnual DPS | — | $4.17 | $0.68 | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.8% | 0.0% | 0.0% | +4.4% |
HOLX leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 3 categories are tied.
RMTI vs BDX vs BAX vs ICU vs HOLX: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is RMTI or BDX or BAX or ICU or HOLX a better buy right now?
For growth investors, Becton, Dickinson and Company (BDX) is the stronger pick with 8.
2% revenue growth year-over-year, versus -31. 8% for Rockwell Medical, Inc. (RMTI). Becton, Dickinson and Company (BDX) offers the better valuation at 25. 6x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate Becton, Dickinson and Company (BDX) a "Hold" — based on 34 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — RMTI or BDX or BAX or ICU or HOLX?
On trailing P/E, Becton, Dickinson and Company (BDX) is the cheapest at 25.
6x versus Hologic, Inc. at 30. 5x. On forward P/E, Baxter International Inc. is actually cheaper at 9. 4x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — RMTI or BDX or BAX or ICU or HOLX?
Over the past 5 years, Hologic, Inc.
(HOLX) delivered a total return of +16. 8%, compared to -98. 3% for SeaStar Medical Holding Corporation (ICU). Over 10 years, the gap is even starker: HOLX returned +124. 3% versus RMTI's -98. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — RMTI or BDX or BAX or ICU or HOLX?
By beta (market sensitivity over 5 years), Hologic, Inc.
(HOLX) is the lower-risk stock at 0. 45β versus Baxter International Inc. 's 1. 38β — meaning BAX is approximately 205% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Rockwell Medical, Inc. (RMTI) carries a lower debt/equity ratio of 34% versus 164% for Baxter International Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — RMTI or BDX or BAX or ICU or HOLX?
By revenue growth (latest reported year), Becton, Dickinson and Company (BDX) is pulling ahead at 8.
2% versus -31. 8% for Rockwell Medical, Inc. (RMTI). On earnings-per-share growth, the picture is similar: SeaStar Medical Holding Corporation grew EPS 78. 1% year-over-year, compared to -495. 2% for Rockwell Medical, Inc.. Over a 3-year CAGR, BDX leads at 5. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — RMTI or BDX or BAX or ICU or HOLX?
Hologic, Inc.
(HOLX) is the more profitable company, earning 13. 8% net margin versus -183. 9% for SeaStar Medical Holding Corporation — meaning it keeps 13. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HOLX leads at 17. 4% versus -132. 2% for ICU. At the gross margin level — before operating expenses — ICU leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is RMTI or BDX or BAX or ICU or HOLX more undervalued right now?
On forward earnings alone, Baxter International Inc.
(BAX) trades at 9. 4x forward P/E versus 17. 2x for Hologic, Inc. — 7. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BDX: 15. 7% to $172. 85.
08Which pays a better dividend — RMTI or BDX or BAX or ICU or HOLX?
In this comparison, BAX (3.
8% yield), BDX (2. 8% yield) pay a dividend. RMTI, ICU, HOLX do not pay a meaningful dividend and should not be held primarily for income.
09Is RMTI or BDX or BAX or ICU or HOLX better for a retirement portfolio?
For long-horizon retirement investors, Becton, Dickinson and Company (BDX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
62), 2. 8% yield). Both have compounded well over 10 years (BDX: +76. 4%, ICU: -98. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between RMTI and BDX and BAX and ICU and HOLX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: RMTI is a small-cap quality compounder stock; BDX is a mid-cap quality compounder stock; BAX is a small-cap income-oriented stock; ICU is a small-cap quality compounder stock; HOLX is a mid-cap quality compounder stock. BDX, BAX pay a dividend while RMTI, ICU, HOLX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.